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EDITORIAL
Mutational analysis of patients with cystinuria detected by a
genetic screening network: Powerful tools in understanding the
several forms of the disorder
Cystinuria, an inherited error of membrane transport
across renal and intestinal epithelium, is an important
cause of renal stone disease with a frequency between
1/2500 live births in Israelis of Libyan origin to 1/15,000 in
North Americans [1]. Of all natural amino acids, cystine
(the mixed disulfide form) is the least soluble in aqueous
solutions, particularly at normal urine pH values between
5.0 and 7.0 [2]. Indeed, it is this relative insolubility of
cystine that results in morbidity, since recurrent renal
stones and infection are the main features of the disorder.
It has been recognized since 1966 that there are three
distinct variants of this disorder [1]. Parents of type I
patients excrete normal amounts of cystine (0 to 100
mmol/g creatinine), those with type III excrete intermedi-
ate amounts (100 to 600 mmol/g creatinine) and type II
excrete greater amounts of cystine (990 to 1740 mmol/g
creatinine). Moreover genetic compounds of cystinuria,
such as type I/III can occur. Historically, it has been
difficult to define the clinical features of each type, partic-
ularly in terms of propensity to stone formation, since most
patients come to medical attention only after a symptom-
atic stone event and anticipatory genetic markers have not
been readily available. Two publications in the current
issue of Kidney International present information that helps
to better define the clinical features and probability of
stone formation in the first decade of life of the various
forms of disease, using both a population and genomic
approach [3, 4].
Since the discovery in 1993 of rBAT [5], the gene
encoding the transporter for cystine and dibasic amino
acids (ornithine, arginine and lysine) transport, it has been
possible to seek out mutations or deletions of SCL3A1, as
the gene is now termed, in the human gene bank. Evident
in subjects with cystinuria [3, 4, 6], this gene is located on
chromosome 2 and clearly represents the site of mutation
for patients with type I or “classical” cystinuria [7]. Type I
patients can be relatively easily identified because their
parents excrete normal amounts of cystine, and because
they commonly have two mutations in the SCL3A1 gene
sequence.
Patients with types II or III do not have mutations in
SCL3A1. Indeed, it is probable that the gene responsible
for types II and III cystinuria is found on chromosome
19q13.1 [8]. This is the form of cystinuria found in the
Israelis of Libyan origin [8]. This gene has not been cloned,
but it presumably codes for a cystine transporter at a
different nephron site than the proximal straight S3 seg-
ment where the SCL3A1 gene product (transporter pro-
tein) is found by in situ hybridization analysis [9].
In this issue, Rozen and Goodyer and their collaborators
have examined 23 children identified by the Quebec screen-
ing program, and have characterized these children in
terms of (1) disease type; (2) history of stone formation;
and (3) presence of an SCL3A1 mutation. The value of the
Quebec population is that they have been observed on a
longitudinal basis, since detection of disease occurred soon
after birth. Moreover, the parental excretion of urinary
cystine has also been assessed. Patients with type I/I
cystinuria, in which parents excrete cystine within the
normal range, had at least two mutations of the SCL3A1
gene in nearly every instance. Between the ages of 1 and 7,
the urinary cystine excretion rate exceeded the solubility
threshold at a given pH on 70 percent of visits. Fifty percent
of these type I/I patients formed stones in the first decade
of life.
Those 12 patients who were compound I/III subjects,
wherein one parent excretes normal urine cystine and the
other excretes moderately elevated amounts, excreted less
cystine than type I/I patients and formed no stones in the
first decade. In only 22% of visits did urine cystine concen-
tration exceed the theoretical solubility threshold. More-
over only one SCL3A1 mutation was found in these 12
patients. The authors make the interesting speculation that
other mutations may account for type I disease, since only
one of twelve children showed the SCL3A1 mutation.
In the Quebec population, type II patients (where het-
erozygotes excrete massive quantities of cystine) are un-
common. Because heterozygotes excrete more than 100
mmol cystine/g creatinine, type II patients may represent a
heterozygous or type II/normal individual. Although these
2 children did not form stones in the first decade of life,
they had family histories consistent with an autosomal
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dominant stone formation over 2 or 3 generations, respec-
tively.
Many unanswered questions remain. There exists a need
to clone and study the second cystine transporter present
on chromosome 19 and determine its location in the
nephron. Because of the degree of cystine excretion in
heterozygotes, this transporter is presumably in the proxi-
mal tubule where bulk amino acid reabsorption occurs. The
full story of SCL3A1 mutations remains to be uncovered.
Do certain racial groups have unique mutations? Are there
polymorphisms of this gene that anthropologists can em-
ploy to map historic migration patterns of man? Will
“increase in function mutations” be found, such as in
Liddle syndrome [10], that result in enhanced cystine
reabsorption? Can we utilize the findings of this prospec-
tive study, where patients are identified by neonatal screen-
ing and genetic analysis, to better define preventative
approaches to lessen or prevent stone formation. Studies
emanating from the Quebec Screening Network have re-
sulted in many achievements in the area of clinical investi-
gations, especially for cystinuria [11]. These two papers
represent a fulfillment of the promise.
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